Oct 8, 2026 07:03AM
Aug 6, 2026 04:20PM
Jul 10, 2026 05:44AM
Jun 2, 2026 06:19AM
May 7, 2026 06:05AM
Apr 29, 2026 07:01AM
Mar 17, 2026 10:12AM Stifel stays Buy rated on X4 Pharmaceuticals (XFOR) as mavorixafor ph3 trial remains on-track
Mar 17, 2026 07:34AM
Mar 9, 2026 06:40AM
Feb 27, 2026 07:03AM
Dec 5, 2025 02:58AM
Nov 10, 2025 06:50AM
Nov 5, 2025 04:12PM
Nov 5, 2025 12:17PM X4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel
Sep 17, 2025 07:13AM
Sep 10, 2025 04:21PM
Aug 29, 2025 07:17AM
Aug 25, 2025 08:16AM
Aug 13, 2025 06:55AM
Aug 12, 2025 03:38PM
Aug 12, 2025 07:01AM X4 Pharmaceuticals secures $60 million financing, replaces CEO and CFO
Jun 16, 2025 08:02AM
Jun 10, 2025 08:02AM
May 2, 2025 07:28AM
May 1, 2025 06:30AM
Apr 24, 2025 08:01AM
Mar 27, 2025 06:40AM
Mar 26, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on X4 Pharmaceuticals (XFOR)
Mar 25, 2025 02:25PM
Mar 25, 2025 10:56AM
Mar 25, 2025 06:10AM
Feb 19, 2025 07:35AM
Feb 6, 2025 07:35AM
Jan 29, 2025 02:48PM
Jan 24, 2025 07:38AM X4 Pharmaceuticals (XFOR) Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Jan 13, 2025 07:35AM
Nov 14, 2024 07:00AM
Nov 13, 2024 04:00PM
Nov 13, 2024 06:24AM
Nov 13, 2024 06:07AM
Aug 8, 2024 06:08AM
Aug 7, 2024 09:54AM Increasing unusual option volume: XFOR LUMN RYAM DT REAL SHLS LAZR ACAD
Jun 28, 2024 06:42AM
Jun 27, 2024 04:00PM
Jun 27, 2024 03:49PM
Jun 27, 2024 06:30AM

466,306 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All